Cultivate cannabis for medical and adult-use markets. Manufacture hemp-derived supplements and cosmetic products. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 7.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 78% of them.
Analysts' average target sits 0% above today's price.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 23% a year on average.
Sales run at $149.2M a year. A small number, but proof the product has real buyers.
There is $831.8M in the vault; even if every debt were paid off, $830.3M would remain.
A loss of $9.6M against $149.2M in annual sales.
On our five-subject report card, CRON sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CRON is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.